Your browser doesn't support javascript.
Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study.
Kikuchi, Kan; Nangaku, Masaomi; Ryuzaki, Munekazu; Yamakawa, Tomoyuki; Yoshihiro, Oota; Hanafusa, Norio; Sakai, Ken; Kanno, Yoshihiko; Ando, Ryoichi; Shinoda, Toshio; Nakamoto, Hidetomo; Akizawa, Tadao.
  • Kikuchi K; Division of Nephrology, Shimoochiai Clinic, 2-1-6 Shimoochiai, Shinjuku-ku, Tokyo, 161-0033 Japan.
  • Nangaku M; Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
  • Ryuzaki M; Department of Nephrology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
  • Yamakawa T; Kidney Center, Shirasagi Hospital, Osaka, Japan.
  • Yoshihiro O; Nagoya Memorial Hospital, Nagoya, Japan.
  • Hanafusa N; Department of Blood Purification, Tokyo Women's Medical University, Tokyo, Japan.
  • Sakai K; Department of Nephrology, Faculty of Medicine,, Toho University, Tokyo, Japan.
  • Kanno Y; Department of Nephrology, Tokyo Medical University, Tokyo, Japan.
  • Ando R; Department of Nephrology, Seishokai Memorial Hospital, Tokyo, Japan.
  • Shinoda T; Faculty of Medical and Health Sciences, Tsukuba International University, Tsuchiura, Japan.
  • Nakamoto H; Department of General Internal Medicine, Saitama Medical University, Iruma, Japan.
  • Akizawa T; Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Ren Replace Ther ; 7(1): 59, 2021.
Article in English | MEDLINE | ID: covidwho-1817287
ABSTRACT

BACKGROUND:

The Japanese Association of Dialysis Physicians, the Japanese Society for Dialysis Therapy, and the Japanese Society of Nephrology jointly established COVID-19 Task Force Committee and began surveying the number of newly infected patients.

METHODS:

This registry of the COVID-19 Task Force Committee was used to collect data of dialysis patients; a total of 1010 dialysis patients with COVID-19 were included in the analysis. Overall survival of patients was investigated with stratification by age group, complication status, and treatment. In addition, predictive factors for mortality were also investigated. The overall survival was estimated by Kaplan-Meier methods and compared by using log-rank test. Multivariate analysis was performed to identify the risk factor of mortality. For all statistical analyses, p < 0.05 was considered to be statistically significant.

RESULTS:

The mortality risk was increased with age (p < 0.001). The mortality risk was significantly higher in patients with peripheral arterial disease (HR 1.49, 95% CI 1.05-2.10) and significantly lower in patients who were treated with remdesivir (HR 0.60, 95% CI 0.37-0.98). Multivariate analysis showed increased risk of mortality with increment in BMI, and increment in CRP, and decreased risk with increment in albumin.

CONCLUSION:

Dialysis patients have a high severity of illness and a high risk of mortality in cases of COVID-19. Treatment with remdesivir might be effective in shortening the duration of hospitalization and reducing the risk of mortality.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: Ren Replace Ther Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: Ren Replace Ther Year: 2021 Document Type: Article